Literature DB >> 22341964

Treatment of status epilepticus in a large community hospital.

Christoph Kellinghaus1, Florian Stögbauer.   

Abstract

BACKGROUND: Status epilepticus (SE) is a neurological emergency usually requiring immediate medical treatment. Due to the lack of adequate studies, treatment guidelines and their application vary between countries and institutions. We intended to analyze current treatment of SE in a German community hospital.
METHODS: We retrospectively identified patients from a large community hospital in northern Germany who had been diagnosed with SE between August 2008 and December 2010. Their charts were reviewed regarding sociodemographic variables, treatment and outcome.
RESULTS: We studied the first SE episode in 172 patients with a median age of 69 years (range 18-90 years). The etiology was acute symptomatic in 30 patients, progressive symptomatic in 22 patients and remote symptomatic in 120 patients. Presentation was generalized convulsive in 60 patients, non-convulsive in 72 patients and simple motor/aura in 40 patients. Median latency from onset to treatment start was 0.75 h (range 0.2-336 h). Initial treatment had a success rate (SR) of 40%. Second line treatment had a success rate of 54%. In patients whose seizures were refractory to the first two drugs, success rates were between 31% and 55%, with only a minority of the patients receiving established drugs such as phenytoin or barbiturates. Multivariate analysis revealed non-convulsive semiology as the only factor significantly associated with refractoriness. SE could be terminated in 95% of the patients and in-hospital mortality was 10%. Benzodiazepines and phenytoin had the most severe side effects.
CONCLUSIONS: Status epilepticus can be terminated successfully and with low in-hospital mortality in the vast majority of the patients treated in a large community hospital. The success rate of each treatment step is between 30% and 55% regardless of the substances used. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341964     DOI: 10.1016/j.yebeh.2011.12.020

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  12 in total

1.  The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Franco Rossetti; Steven L Miller; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2014-08-25       Impact factor: 4.030

Review 2.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

3.  Usefulness of intravenous lacosamide in status epilepticus.

Authors:  Estevo Santamarina; Manuel Toledo; Maria Sueiras; Miquel Raspall; Nadim Ailouti; Elena Lainez; Isabel Porta; R De Gracia; Manuel Quintana; Javier Alvarez-Sabín; Xavier Salas Puig Xavier Salas Puig
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

4.  Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study.

Authors:  Annalena Hottinger; Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

5.  Therapeutic coma for status epilepticus: Differing practices in a prospective multicenter study.

Authors:  Vincent Alvarez; Jong Woo Lee; M Brandon Westover; Frank W Drislane; Jan Novy; Mohamed Faouzi; Nicola A Marchi; Barbara A Dworetzky; Andrea O Rossetti
Journal:  Neurology       Date:  2016-09-24       Impact factor: 9.910

Review 6.  Neurosteroids for the potential protection of humans against organophosphate toxicity.

Authors:  Doodipala Samba Reddy
Journal:  Ann N Y Acad Sci       Date:  2016-07-23       Impact factor: 5.691

7.  Acute antiepileptic drug use in intensive care units.

Authors:  Bernd J Vorderwülbecke; Gregor Lichtner; Falk von Dincklage; Martin Holtkamp
Journal:  J Neurol       Date:  2018-09-26       Impact factor: 4.849

8.  LY293558 prevents soman-induced pathophysiological alterations in the basolateral amygdala and the development of anxiety.

Authors:  Eric M Prager; Taiza H Figueiredo; Robert P Long; Vassiliki Aroniadou-Anderjaska; James P Apland; Maria F M Braga
Journal:  Neuropharmacology       Date:  2014-09-06       Impact factor: 5.250

9.  Making SENSE--Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry.

Authors:  Christoph Kellinghaus; Nicolas Lang; Andrea O Rossetti; Stephan Rüegg; Christian Tilz; Eugen Trinka; Iris Unterberger; Zeljko Uzelac; Felix Rosenow
Journal:  BMC Neurol       Date:  2015-11-10       Impact factor: 2.474

10.  (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study.

Authors:  Julia Höfler; Alexandra Rohracher; Gudrun Kalss; Georg Zimmermann; Judith Dobesberger; Georg Pilz; Markus Leitinger; Giorgi Kuchukhidze; Kevin Butz; Alexandra Taylor; Helmut Novak; Eugen Trinka
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.